$14.68
2.49% today
Nasdaq, Apr 03, 06:45 pm CET
ISIN
US0352551081
Symbol
ANIK
Sector
Industry

Anika Therapeutics, Inc. Stock price

$15.05
-2.15 12.50% 1M
-9.97 39.85% 6M
-1.41 8.57% YTD
-10.78 41.73% 1Y
-10.48 41.05% 3Y
-14.63 49.29% 5Y
-25.82 63.18% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.02 0.13%
ISIN
US0352551081
Symbol
ANIK
Sector
Industry

Key metrics

Market capitalization $213.35m
Enterprise Value $183.65m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.21
P/S ratio (TTM) P/S ratio 1.41
P/B ratio (TTM) P/B ratio 1.41
Revenue growth (TTM) Revenue growth -8.92%
Revenue (TTM) Revenue $151.80m
EBIT (operating result TTM) EBIT $-30.52m
Free Cash Flow (TTM) Free Cash Flow $-2.33m
Cash position $55.63m
EPS (TTM) EPS $-3.84
P/E forward negative
P/S forward 1.90
EV/Sales forward 1.63
Short interest 3.89%
Show more

Is Anika Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Anika Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Anika Therapeutics, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Anika Therapeutics, Inc. forecast:

Buy
100%

Financial data from Anika Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
152 152
9% 9%
100%
- Direct Costs 81 81
28% 28%
54%
71 71
32% 32%
46%
- Selling and Administrative Expenses 63 63
21% 21%
42%
- Research and Development Expense 29 29
10% 10%
19%
-22 -22
131% 131%
-15%
- Depreciation and Amortization 8.28 8.28
48% 48%
5%
EBIT (Operating Income) EBIT -31 -31
20% 20%
-20%
Net Profit -56 -56
32% 32%
-37%

In millions USD.

Don't miss a Thing! We will send you all news about Anika Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Anika Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
22 days ago
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q4 2024 Earnings Conference Call March 12, 2025 5:00 PM ET Company Participants Matt Hall - Director, Corporate Development & Investor Relations Cheryl Blanchard - President & Chief Executive Officer Steve Griffin - Executive Vice President, Chief Financial Officer & Treasurer Conference Call Participants Jim Sidoti - Sidoti & Co. Mike Petusky - Barringto...
Neutral
GlobeNewsWire
22 days ago
Full Year 2024 results in line with guidance with Commercial Channel revenue up 17% Strong International OA Pain Management and greater than 40% sequential growth of Integrity™ Implant System drive Commercial Channel growth and 2024 results Key Regulatory and Clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Strategic Sale of Parcus Medical complete; resources refocused on pro...
Neutral
GlobeNewsWire
27 days ago
Execution of Previously Announced Plan Sharpens Focus on Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio Execution of Previously Announced Plan Sharpens Focus on Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio
More Anika Therapeutics, Inc. News

Company Profile

Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.

Head office United States
CEO Cheryl Blanchard
Employees 288
Founded 1992
Website www.anika.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today